DOI QR코드

DOI QR Code

Expression of Ki67 in Papillary Thyroid Microcarcinoma and its Clinical Significance

  • Zhou, Yuan (Department of surgical oncology, Shanghai Jiao Tong University Affiliated First People's Hospital Jiaxing Branch, Jiaxing First Hospital) ;
  • Jiang, Hong-Gang (Department of surgical oncology, Shanghai Jiao Tong University Affiliated First People's Hospital Jiaxing Branch, Jiaxing First Hospital) ;
  • Lu, Ning (Department of surgical oncology, Shanghai Jiao Tong University Affiliated First People's Hospital Jiaxing Branch, Jiaxing First Hospital) ;
  • Lu, Bo-Hao (Department of surgical oncology, Shanghai Jiao Tong University Affiliated First People's Hospital Jiaxing Branch, Jiaxing First Hospital) ;
  • Chen, Zhi-Heng (Department of surgical oncology, Shanghai Jiao Tong University Affiliated First People's Hospital Jiaxing Branch, Jiaxing First Hospital)
  • Published : 2015.03.09

Abstract

Purpose: To investigate the expression of Ki67 protein in papillary thyroid microcarcinoma(PTMC), and to analyze its clinical significance. Materials and Methods: Ki67 protein expression was evaluated in the tissues of 108 human PTMC and 50 other benign papillary hyperplasia of thyroid specimens using immunohistochemistry. Results: The expression intensity of Ki67 in PTMC and benign papillary hyperplasia of thyroid specimens were $1.45{\pm}1.83%$ and $0.46{\pm}0.46%$.The positive expression rates were 46.3% and 14%. There were significant differences between these two groups (p<0.01). There was no significant variation of the expression intensity and positive expression rates of Ki67 in PTMC with gender, age, position of the tumor and the level of TSH pre-operation (p>0.05), but these parameters varied with tumor size, invasion by membrane and cervical lymph node metastasis (p<0.05 or p<0.01). Conclusions: The expression of Ki67 in PTMC was related to tumor size, invasion by membrane and cervical lymph node metastasis, and could be the important indicator for judging clinical progress and estimating prognosis.

Keywords

Papillary thyroid microcarcinoma;immunohistochemistry;Ki67

References

  1. Aiad HA, Bashandy MA, Abdou AG, et al (2013). Significance of AgNORs and ki67 proliferative markers in differential diagnosis of thyroid lesions. Pthol Oncol Res, 19, 167-75. https://doi.org/10.1007/s12253-012-9565-1
  2. Arshad H, Ahmad Z, Hasan SH (2010). Gliomas: correlation of histologic grade, Ki67 and p53 expression with patient survival. Asian Pac J Cancer Prev, 11, 1637-40.
  3. Beesley MF, Mclaren KM (2002). Cytokeratin19 and galectin-3 inmunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology, 41, 236-43. https://doi.org/10.1046/j.1365-2559.2002.01442.x
  4. Chen Y, Klingen TA, Wik E, et al (2014). Breast cancer stromal elastosis is associated with mammography screening detection, low Ki67 expression and favourable prognosis in a population-based study. Diagn Pathol, 9, 230. https://doi.org/10.1186/s13000-014-0230-8
  5. Choudhury M, Singh S, Agarwal S, et al (2011). Diagnostic utility of Ki67 and p53 immunostaining on solitary thyroid nodule--a cytohistological and radionuclide scintigraphic study. Indian J Pathol Microbiol, 54, 472-5. https://doi.org/10.4103/0377-4929.85077
  6. Haroon S, Hashmi AA, Khurshid A, et al (2013). Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients. Asian Pac J Cancer Prev, 14, 4353-8. https://doi.org/10.7314/APJCP.2013.14.7.4353
  7. Hughes DT, Haymart MR, Miller BS, et al (2011). The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid, 21, 231-6. https://doi.org/10.1089/thy.2010.0137
  8. Jeon SI, Kim E, Park JS, et al (2009). Diagnostic benefit of thyroglobulin measurement in fine-needle aspiration for diagnosing metastatic cervical lymph nodes from papillary thyroid cancer correlations with US features. Korean J Radiol, 10, 106-11. https://doi.org/10.3348/kjr.2009.10.2.106
  9. Klintman M, Bendahl PO, Graban D, et a1 (2010). The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol, 23, 251-9. https://doi.org/10.1038/modpathol.2009.167
  10. Tadbir AA, Pardis S, Ashkavandi ZJ, et al (2012). Expression of Ki67 and CD105 as proliferation and angiogenesis markers in salivary gland tumors. Asian Pac J Cancer Prev, 13, 5155-9. https://doi.org/10.7314/APJCP.2012.13.10.5155
  11. Ye WJ, Xing WB, Qin LY, et al (2010). The expression and the correlational analysis of Survivin and Ki67 in the tissues of squamous cell carcinoma and basal cell epithelioma. The Chinese J Dermatovenereology, 24, 20-2.
  12. Zafon C, Baena JA, Castellvi J, et al (2010). Differences in the form of presentation between papillary microcarcinoma and papillary carcinomas of larger size. J Thyroid Res, 2011, 639156.
  13. Zhang HX, Su C, Xie J (2010). Clinical pathology analysis of 66 cases thyroid microcarcinoma. Chinese J Cancer Prev Treat, 17, 1880-1.

Cited by

  1. Somatostatin Receptor 2 and 5 Expressions in Gastroenteropancreatic Neuroendocrine Tumors in Turkey vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4377
  2. Could Tumor Size Be A Predictor for Papillary Thyroid Microcarcinoma: a Retrospective Cohort Study vol.16, pp.18, 2016, https://doi.org/10.7314/APJCP.2015.16.18.8625
  3. Pathological characteristics of low-risk papillary thyroid microcarcinoma with progression during active surveillance vol.63, pp.9, 2016, https://doi.org/10.1507/endocrj.EJ16-0097
  4. Ki-67 is overexpressed in human laryngeal carcinoma and contributes to the proliferation of HEp2 cells vol.12, pp.4, 2016, https://doi.org/10.3892/ol.2016.4980
  5. Preventive Potential of Resveratrol in Carcinogen-Induced Rat Thyroid Tumorigenesis vol.10, pp.3, 2018, https://doi.org/10.3390/nu10030279
  6. The clinicopathological significance of Ki67 in papillary thyroid carcinoma: a suitable indicator? vol.16, pp.1, 2018, https://doi.org/10.1186/s12957-018-1384-8